ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
Holistic Investigation of Graphene Quantum Dot Endocytosis.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Evaluating cellular responses of lung and liver cells to graphene oxide functionalized poly(propylene)imine and polyamidoamine dendrimers: insights for biomedical applications.Discover nano · 2026Article
- Precursor-dependent optical and structural properties of eleven NIR-emissive graphene quantum dots for bioimaging applications.2d materials · 2026Article
- Applications of Carbon Dots and Graphene Quantum Dots in Treatment of Diabetes.Molecules (Basel, Switzerland) · 2026Review
- Electrochemically Engineered GQDs for Selective Tumor Targeting and Oxidative Nanotherapy in Triple-Negative Breast Cancer.ACS omega · 2026Article
- Graphene-Based Materials: A Multifunctional Platform for Comprehensive Perioperative Management of Cancer.International journal of nanomedicine · 2026Review
- Graphene quantum dot-integrated nanocomposites: a promising avenue for glioblastoma treatment.Medical oncology (Northwood, London, England) · 2025Review
- Holistic Investigation of Graphene Quantum Dot Endocytosis.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Graphene quantum dots (GQDs) have gained popularity in nano-biotechnology due to their multifunctional delivery and imaging capabilities. The outcome of their therapeutic delivery applications relies on understanding cell internalization routes. Current literature presents often conflicting results based on surveying only a few endocytosis inhibitors. Herein, a holistic approach to cell uptake studies by utilizing six different inhibitors while considering their on- and off-target effects on internalization of the GQDs of different charges is provided. Endocytosis paths are explored by tracking intracellular GQD fluorescence in HeLa or HEK-293 cells. Contrary to the previous assumptions of a singular entry route, findings suggest that GQDs enter the cells through several endocytosis paths with some more prevalent than others. Selectivity between the pathways is based on GQD charge and functional groups. Positively charged nitrogen-doped GQDs (NGQDs) predominantly utilize a fast endophilin-mediated endocytosis (FEME) in HeLa cells with a secondary preference for clathrin-mediated endocytosis (CME). In HEK-293 cells NGQDs internalize via clathrin-independent, glycosylphosphatidylinositol-anchored protein-enriched compartments (CLIC/GEEC) and FEME. Conversely, GQDs with a substantial negative surface charge uptake through CME in HeLa cells. The optimization of these mechanisms can enhance GQD applications in biomedicine, ideally streamlining their translation into the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.